Investors
Featured Press Release
Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection BARHEMSYS ® (amisulpride for injection) and BYFAVO ® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per year 1 addressable market and projected
See More
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter -- -- Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S.
See More
WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference as
See More
Upcoming Events & Presentations
No items found.